Dai Zhi-Ming, Liu Jie, Cao Xing-Mei, Zhang Yang, Wang Meng, Liu Xing-Han, Li Chang-Ji, Dai Zhi-Jun, Zhang Wang-Gang
1 Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China .
2 Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an, China .
Genet Test Mol Biomarkers. 2015 Jun;19(6):324-30. doi: 10.1089/gtmb.2015.0024. Epub 2015 May 8.
Previous studies investigated the associations of interleukin-10 (IL-10) polymorphisms with different types of cancer, indicating an influence on cancer risk. IL-10-3575T>A (rs1800890) has been studied concerning a potential implication in terms of some cancer site risks, but the results from single studies are contradictory.
Eligible articles were identified by a search of the PubMed, Web of Science, and Chinese National Knowledge Infrastructure (CNKI) databases until November 30, 2014. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the cancer risk by cancer sites, ethnicity, and other study features.
We identified 15 published studies to research the link of the IL-10-3575T>A polymorphism with cancer risk. Our meta-analysis indicated that the IL-10-3575T>A polymorphism has a significant association with decreased melanoma risk in the heterozygote model (OR=0.67, 95% CI=0.49-0.92, p=0.02) and dominant model (OR=0.70, 95% CI=0.52-0.95, p=0.01), but increased diffuse large B-cell lymphoma (DLBCL) risk in all the different genetic models.
Our analysis suggests that the IL-10-3575T>A mutation may associate with melanoma and DLBCL and exert a differential effect in different cancer sites. However, other factors may influence the association, and large-scale multicenter with adequate methodological quality studies are needed to confirm the impact on cancer susceptibility.
既往研究调查了白细胞介素-10（IL-10）基因多态性与不同类型癌症的关联，提示其对癌症风险有影响。关于IL-10 -3575T>A（rs1800890）在某些癌症部位风险方面的潜在影响已有研究，但单项研究结果相互矛盾。
通过检索PubMed、科学网和中国知网数据库确定符合条件的文章，检索截止至2014年11月30日。采用粗比值比（OR）及95%置信区间（CI），按癌症部位、种族和其他研究特征评估癌症风险。
我们纳入了15项已发表的研究来探讨IL-10 -3575T>A多态性与癌症风险的关系。我们的荟萃分析表明，在杂合子模型（OR = 0.67，95%CI = 0.49 - 0.92，p = 0.02）和显性模型（OR = 0.70，95%CI = 0.52 - 0.95，p = 0.01）中，IL-10 -3575T>A多态性与黑色素瘤风险降低显著相关，但在所有不同遗传模型中均与弥漫性大B细胞淋巴瘤（DLBCL）风险增加相关。
我们的分析表明，IL-10 -3575T>A突变可能与黑色素瘤和DLBCL相关，并在不同癌症部位发挥不同作用。然而，其他因素可能影响这种关联，需要大规模多中心且方法学质量足够的研究来证实其对癌症易感性的影响。
